Maves Review
Semaglutide & tirzepatide GLP-1 weight-loss telehealth · Independently scored 7.2/10
Best for: performance-framed compounded GLP-1 with sermorelin and NAD+ protocol bundles
Maves scores highest on the strength of its clinical program: drug options and dosing support.
Semaglutide
then $249/mo ongoing
Tirzepatide
then $349/mo ongoing
Price checked on Maves’s site,
What the monthly price covers
Medication
Included
Provider visits
Included
Shipping
Included
Lab work
Not stated
Coaching
Not stated
No insurance needed · Vetted by our editors
Maves is a performance-framed telehealth brand from Homera Health that prescribes compounded semaglutide and tirzepatide alongside sermorelin and NAD+, including protocol bundles that pair a GLP-1 with sermorelin. Plans bundle the clinician review, medication, a home injection kit and free expedited shipping. Semaglutide is $189 the first month, then $249/mo; tirzepatide is $249 the first month, then $349/mo.
WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. How we make money
Vetted alternatives to Maves
Ro
Best for: FDA-approved brand GLP-1s, including the Wegovy pill and Foundayo, with insurance help
Editorial score · methodology
Collective
Best for: the lowest flat medication price if you can absorb an annual membership fee
Editorial score · methodology
CoreAge Rx
Best for: lowest-price compounded semaglutide and tirzepatide with one flat price at every dose
Editorial score · methodology
Maves at a glance
- Type
- GLP-1 telehealth provider
- Medications
- Semaglutide, Tirzepatide
- Starting price
- $249/mo (after intro offer) ($189 first month)
- What's included
- Medication · Consult · Shipping
- Availability
- 35 states
- FDA status
- No FDA warning letter on record
How we scored Maves
Each dimension is scored algorithmically from Maves’s published pricing, drugs offered, verification status, and disclosed inclusions, using the same six-dimension framework we apply to every provider.
Value25%
6.1/10At $249/mo (after intro offer), Maves runs about 39% above the $179 median for GLP-1 providers (each program's lowest listed ongoing monthly price for compounded semaglutide), with an intro price of $189.
Effectiveness25%
8.0/10Maves offers both semaglutide and tirzepatide, the two GLP-1 molecules with the strongest published weight-loss trial outcomes.
User Experience15%
7.3/10Online intake and platform experience (consult included in the price); 8 platform features disclosed.
Trust & Safety15%
8.0/10Key details fully confirmed by our editors; no FDA warning letters on file.
Accessibility10%
7.6/10Maves is available in 35 states. FSA/HSA cards are accepted.
Support10%
5.8/10Maves provides standard clinician follow-up; no extended coaching or community program is disclosed.
Each checked against the provider’s own site.
Providers that don’t post pricing up front score lower on Value and carry a cost-transparency note in their review. Read the full methodology →
How we verified this Maves review
Last checked October 2026- Confirmed current pricing across 2 dose/plan tiers
- Confirmed availability in 35 states
- Confirmed what the monthly price does and doesn't include
- Checked the FDA warning-letter database for enforcement actions
- Walked the provider's public sign-up flow, stopping before payment
Pricing, availability, and compliance facts come from the provider's own site and primary regulatory records. See the sources below. Editorial confidence in this data: high.
What we checked
- Provider's own pricing page
- $249–$349/mo across 2 dose/plan tiers (checked October 2026)
- State pharmacy licensing & LegitScript status
- LegitScript Verified
- FDA warning-letter register
- No letter on file for this provider
What to expect when you sign up with Maves
We walked Maves’s public signup flow in October 2026 to document the process (the steps, pricing transparency, and what’s required) before you commit. (We don’t create accounts, enter medical information, or check out; this is the observable funnel, not a prescribing outcome.)
- 1Pick GLP-1 (semaglutide or tirzepatide) or a protocol bundle on Maves' website; each treatment page shows the first-month and ongoing price
- 2Click 'See if I qualify', which opens a 34-step online intake in the Maves patient app
- 3Step 1 asks for your state and requires checking a box that accepts the Terms, Privacy Policy and Telehealth Consent
- Prices are shown before any intake: semaglutide $189 first month then $249/mo, tirzepatide $249 then $349/mo, with the discount auto-applied
- The state picker lists 35 states, while the FAQ says only 'select U.S. states'
- Product pages promise 'If you don't qualify, you don't pay' and 'Cancel anytime'; the terms add that membership fees are non-refundable once paid
- The site says a U.S.-licensed clinician reviews your case within 24 hours; no video visit is mentioned for GLP-1
- The homepage says 'delivered in days', but the shipping policy quotes 2-3 business days to process and 4-12 business days in transit
- The site shows a '4.7' average rating without naming the source; Maves' Trustpilot page had 4 reviews
Maves customer support
- Phone
- +1-307-317-6388
GLP-1 medications Maves offers
Tap any medication to read our plain-English guide: how it works, dosing, side effects, and what the trials found.
Peptides Maves offers
Beyond GLP-1s, Maves also offers these peptides. Tap any for our evidence-based guide.
Pricing
Prices re-verified
$189 first month (discount auto-applied), then $249 per billing cycle. Includes clinician care, medication, home injection kit and free expedited shipping.
$249 first month (discount auto-applied), then $349 per billing cycle. Includes clinician care, medication, home injection kit and free expedited shipping.
Ready to get started?
Plans and promotions change often, so check Maves's current pricing and active discounts before you decide.
What we like
- Names its partner pharmacies (GoGoMeds and Red Rock Pharmacy) and its clinical groups in its terms
- First-month and ongoing prices are shown on every treatment page, with the discount applied automatically
- Plan price bundles clinician care, medication, a home injection kit and free expedited shipping
- You don't pay if a clinician decides you don't qualify
- Cancel anytime by phone, email or from your account
- HSA/FSA eligible
- Names a chief medical officer and publishes the FDA compounded-medication disclaimer
- LegitScript-certified seal on the site
Watch-outs
- Ongoing price is $249/mo for semaglutide and $349/mo for tirzepatide, well above the first-month rate
- Billed roughly every 28-30 days, so you can see more than 12 charges a year
- Membership fees are non-refundable once paid, and prescription sales are final
- Serves 35 states, not all 50
- Shipping policy quotes 2-3 business days to process plus 4-12 business days for delivery
- Terms say lab work may be required and would be billed separately by Quest Diagnostics
- Disputes go to binding arbitration in New York under Delaware law
Maves: a performance-framed GLP-1 plan with a first-month discount
Maves is the consumer brand of Homera Health, and it sells weight loss differently than most telehealth clinics. Instead of the usual disease-and-BMI framing, it leans into a body-optimization pitch built around fat loss, lean muscle and energy, and it pairs compounded semaglutide and tirzepatide with sermorelin and NAD+, add-ons you won't find at a typical GLP-1 startup. The prices are now posted in full, for the first month and every refill after it. The trade-offs are a narrower state footprint than before and strict refund terms.
How the pricing works
Semaglutide costs $189 for the first month, with the discount applied automatically, and $249 (after intro offer) per billing cycle after that. Tirzepatide follows the same pattern, at $249 for month one and then $349 for each refill. Both prices sit on each treatment page before you start the intake, which is more than many competitors show. The ongoing semaglutide rate is above the $179 category median we track, so this is not a budget pick past month one.
How we get the market median: $179 is the middle value of each program's lowest listed ongoing monthly price for compounded semaglutide (month to month, not a first-month promo, a prepaid plan or a price with a membership on top), across the 121 programs that publish one.
Watch the billing cadence, because the terms say you're charged about every 28 to 30 days rather than once a calendar month. That can mean more than 12 charges a year. The plan price does bundle a lot: the clinician review, your medication, a home injection kit and free expedited shipping. Sermorelin starts at $199 a month and NAD+ at $229, each sold separately or in protocol bundles.
- Semaglutide: $189 for the first month, then $249 (after intro offer) for every billing cycle after that
- Tirzepatide: $249 for the first month, then $349 for every billing cycle after that
- Sermorelin and NAD+: optional add-ons starting at $199 and $229 a month, also sold in protocol bundles
- Bundled in every plan: clinician care, medication, injection kit, free expedited shipping
The medications and who fills them
Maves dispenses compounded semaglutide and tirzepatide only, with no brand-name pens on the menu. Brand-name options and video coaching are both on offer at NuDay Rx, next to its compounded menu. These are the same active ingredients as Wegovy and Zepbound, made to order by a compounding pharmacy. The terms now name the partner pharmacies: GoGoMeds, based in Southgate, Kentucky, and Red Rock Pharmacy. That's an improvement, since you can look either one up yourself, and Maves also posts the FDA's compounded-medication disclaimer on its safety-information page.
Positioning and disclosure
The performance positioning is the obvious one: Maves frames GLP-1 therapy around body composition and folds in sermorelin and NAD+, which will resonate with people who think about their bodies in those terms. The other is disclosure, because the terms name Homera Health LLC, the clinical groups (Beluga Health and Keeva Medical Group) and the pharmacies. Product pages also name a chief medical officer, Dr. Michael Green, and few single-brand shops are this open about who is behind the care.
Who it's for, and who should skip it
Maves fits someone drawn to the body-optimization framing who wants posted prices and an all-inclusive plan. It also suits anyone who wants a GLP-1 and sermorelin from one place. A clinician reviews your case within 24 hours, and you don't pay if you don't qualify.
Skip it if you live outside its footprint, since the intake lists 35 states rather than all 50. Peak Wellness says it serves all 50 states and names its pharmacies. Skip it, too, if price after month one is your main filter. Membership fees are non-refundable once paid, prescription sales are final, and disputes go to binding arbitration in New York under Delaware law. The shipping policy also quotes up to 12 business days in transit, slower than the homepage implies.
Trust, safety, and medical oversight
Maves shows a LegitScript seal on its site, which is the main third-party accreditation for a telehealth pharmacy operation, and it sits alongside a clear paper trail. Maves names its pharmacies, its clinical groups and a chief medical officer. It also publishes the FDA compounded disclaimer, and there are no FDA warning letters on file against it. One soft spot: the site shows a 4.7 rating without naming the source, and its Trustpilot page has only four reviews. You can read how we weigh these factors in our scoring methodology.
Bottom line
Maves is a well-disclosed, LegitScript-sealed way to start compounded semaglutide or tirzepatide with a performance-and-recovery pitch. It now shows exactly what you pay, names its pharmacies and names its medical lead. The drawback is cost over time, because at $249 (after intro offer) for semaglutide after month one, billed every four weeks or so, it costs more than the median plan. Check that your state is on the list, and plan around the no-refund terms.
The Bottom Line
Maves scores highest on the strength of its clinical program: drug options and dosing support.
Ready to start with Maves?
From $249/mo (after intro offer). See current pricing and start your free consultation.
Maves might not be your best fit if…
We rank editorially, so here’s where a different provider we track may serve you better.
Head-to-head
Compare Maves vs…
Maves scores7.2/10
Side-by-side pricing, medications and scores. Pick a matchup.
Maves vs Amazon One Medical
Amazon One Medical scores 8.5/10

Maves vs Vytora Health
Vytora Health scores 8.4/10
Scores are our independent editorial ratings out of 10.
Frequently Asked Questions
Key terms, explained
New to GLP-1s? Tap any term for a quick, plain-English definition.
- Semaglutide · Drugs and brands
- Tirzepatide · Drugs and brands
- Compounded GLP-1 · Pharmacy and drug forms
- 503A pharmacy · Pharmacy and drug forms
- PCAB accreditation · Pharmacy and drug forms
- Prior authorization (PA) · Insurance and regulatory
- Off-label use · Insurance and regulatory
- FDA Drug Shortage List · Insurance and regulatory
Sources
The primary regulatory filings and peer-reviewed studies cited throughout this Maves review:
Sources & methodology (as of November 2026)
- 1.Weight Loss Rankings — GLP-1 Pricing Index 2026 (our independent dataset)— WeightLossRankings.org.
- 2.FDA — Compounding and the 503A Pharmacy Framework— U.S. Food & Drug Administration.
- 3.FDA — Drug Shortages Database (current shortage listings)— U.S. Food & Drug Administration.
- 4.PCAB — Pharmacy Compounding Accreditation Board Standards— Accreditation Commission for Health Care (ACHC) / PCAB.
- 5.KFF — Medicaid coverage research (anti-obesity & GLP-1 drug policy)— Kaiser Family Foundation.
- 6.STEP 1 Trial — Once-Weekly Semaglutide in Adults with Overweight or Obesity (Wilding JPH et al.)— New England Journal of Medicine.PMID: 33567185.
- 7.FDA — Wegovy (semaglutide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
- 8.FDA — Ozempic (semaglutide) Prescribing Information via Drugs@FDA— U.S. Food & Drug Administration.
- 9.SURMOUNT-1 Trial — Tirzepatide Once Weekly for the Treatment of Obesity (Jastreboff AM et al.)— New England Journal of Medicine.PMID: 35658024.
- 10.FDA — Zepbound (tirzepatide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
- 11.FDA — Mounjaro (tirzepatide) Prescribing Information via Drugs@FDA— U.S. Food & Drug Administration.
- 12.SURMOUNT-5 Trial — Tirzepatide vs. Semaglutide Head-to-Head in Obesity (Garvey WT et al.)— New England Journal of Medicine.PMID: 40334173.
See Maves's current pricing
Plans from $249/mo (after intro offer). Start your free consultation to check eligibility and today's price.